IMDX
Insight Molecular Diagnostics Inc.
NASDAQ: IMDX · HEALTHCARE · DIAGNOSTICS & RESEARCH
$3.83
-8.81% today
Updated 2026-04-29
Market cap
$123.53M
P/E ratio
—
P/S ratio
30.46x
EPS (TTM)
$-1.65
Dividend yield
—
52W range
$2 – $9
Volume
0.3M
Insight Molecular Diagnostics Inc. (IMDX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-11.4%
Last 4 quarters
Revenue YoY growth
-23.4%
Most recent quarter
EPS YoY growth
+62.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-8.7%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-38.0%
2026-03-27
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-27 | $-0.72 | -203.2% | $4.11 | $2.55 | -38.0% |
| 2025-11-10 | $-0.34 | +41.4% | $6.24 | $7.53 | +20.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.24 | $-0.72 | -203.2% | $1.14M | -23.4% |
| 2025-09-30 | $-0.58 | $-0.34 | +41.4% | $260000.00 | +126.1% |
| 2025-06-30 | $-0.63 | $-0.30 | +52.4% | $518000.00 | +398.1% |
| 2025-03-31 | $-0.66 | $-0.26 | +60.6% | $2.14M | +1114.8% |
| 2024-12-31 | $-1.12 | $-1.93 | -72.3% | $1.49M | — |
| 2024-09-30 | $-0.44 | $-0.98 | -124.4% | $115000.00 | -73.2% |
| 2024-06-30 | $-0.37 | $-0.43 | -16.8% | $104000.00 | -77.5% |
| 2024-03-31 | — | $-1.13 | — | $176000.00 | -40.7% |
| 2023-09-30 | $-1.01 | $-0.81 | +19.8% | $429000.00 | — |
| 2023-06-30 | $-0.87 | $-1.03 | -18.4% | $463000.00 | — |
| 2023-03-31 | $-0.08 | $0.04 | +150.0% | $297000.00 | — |
| 2022-12-31 | $-0.09 | $-0.40 | -326.4% | — | — |
Frequently asked questions
Has Insight Molecular Diagnostics Inc. beaten earnings estimates?
Insight Molecular Diagnostics Inc. has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -11.4% over the last 4 quarters.
How does IMDX stock react to earnings?
IMDX stock has moved an average of -8.7% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Insight Molecular Diagnostics Inc.'s revenue growth rate?
Insight Molecular Diagnostics Inc. reported year-over-year revenue growth of -23.4% in its most recent quarter, with EPS growing +62.7% year-over-year.